New Sleep Apnea Pill Reduces Episodes by 47% in Trials

A medication originally developed to treat epilepsy in Europe has demonstrated remarkable efficacy in reducing sleep apnea episodes by up to 47% in large-scale clinical trials. The oral drug offers a non-invasive alternative to CPAP machines, which many patients struggle to use consistently.

Sleep apnea affects millions of people worldwide, causing disrupted sleep, daytime fatigue, and increasing risks of heart disease and stroke. Despite its prevalence, treatment options have been limited, with CPAP machines remaining the gold standard despite low patient compliance.

An effective pill could transform treatment outcomes for millions. Rather than strapping on a mask and hose every night, patients could simply take a medication before bed — dramatically improving quality of life and treatment adherence.

The drug's origins in epilepsy treatment also highlight how cross-pollination between medical specialties can yield unexpected breakthroughs. What works for one condition may hold the key to treating another entirely.